These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 585506)

  • 21. Problems in pharmacological evaluation of potential antiparkinson agents.
    Metysová J; Metys J; Dlabac A
    Act Nerv Super (Praha); 1978 Feb; 20(1):55-6. PubMed ID: 565123
    [No Abstract]   [Full Text] [Related]  

  • 22. [Letter: Intoxicating abuse of antiparkinson drugs].
    Hartvig P
    Tidsskr Nor Laegeforen; 1973 May; 93(13):957. PubMed ID: 4751597
    [No Abstract]   [Full Text] [Related]  

  • 23. [Drug interactions of central nervous system active drugs. 3: Drug interactions of anticonvulsants and antiparkinson agents].
    Estler CJ
    Fortschr Med; 1984 Feb; 102(6):129-32. PubMed ID: 6706270
    [No Abstract]   [Full Text] [Related]  

  • 24. [Monitoring of antiparkinson treatment].
    Nègre C
    Soins; 1986 Mar; (474):17-8. PubMed ID: 3638795
    [No Abstract]   [Full Text] [Related]  

  • 25. [Withdrawal of antiparkinson drugs in long term neuroleptic treatment].
    Lerner J; Blum E; Fuchs I; Grinberg M
    Harefuah; 1978 Oct; 95(8):239-41. PubMed ID: 33879
    [No Abstract]   [Full Text] [Related]  

  • 26. [Antiviral chemotherapeutic agents. XVIII. Adamantane derivatives of amphetamine. Their potential interest as autonomic and antiparkinson agents].
    Runti C; De Nardo M; Fabrissin S
    Farmaco Sci; 1975 Apr; 30(4):260-75. PubMed ID: 241665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiparkinson medications improve agonist activation but not antagonist inhibition during sequential reaching movements.
    Kelly VE; Bastian AJ
    Mov Disord; 2005 Jun; 20(6):694-704. PubMed ID: 15719427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abuse of the antiparkinson drugs: a review of the literature.
    Smith JM
    J Clin Psychiatry; 1980 Oct; 41(10):351-4. PubMed ID: 7430078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Withdrawal of non-dopaminergic antiparkinson drugs].
    Le Bellec M; George V
    J Toxicol Clin Exp; 1985; 5(1):47-53. PubMed ID: 3843760
    [No Abstract]   [Full Text] [Related]  

  • 30. [Synthesis and testing of potential antiparkinson agents. 2. Biologically active silicium derivatives].
    Friedrich G; Bartsch R; Rühlmann K
    Pharmazie; 1977 Jul; 32(7):394-7. PubMed ID: 909903
    [No Abstract]   [Full Text] [Related]  

  • 31. [Epidemic tremor in chickens as a model for the testing of antiparkinson drugs].
    Stern P; Srebocan S; Cvetnić S; Brmalj V
    Acta Biol Med Ger; 1973; 31(3):463-5. PubMed ID: 4775352
    [No Abstract]   [Full Text] [Related]  

  • 32. [Use of anticholinergic antiparkinson agents against adverse drug reactions in a psychiatric department. A quality assurance project].
    Mikkelsen VR
    Ugeskr Laeger; 1998 Jul; 160(29):4323-5. PubMed ID: 9679438
    [No Abstract]   [Full Text] [Related]  

  • 33. [A practical guide for the use of psychopharmacologic agents. II. Antipsychotic and antiparkinson agents].
    Chouinard G
    Union Med Can; 1976 Sep; 105(9):1387-97. PubMed ID: 9720
    [No Abstract]   [Full Text] [Related]  

  • 34. On the interaction between neuroleptics and antiparkinson drugs.
    Julou L
    Mod Probl Pharmacopsychiatry; 1970; 5():50-4. PubMed ID: 5527168
    [No Abstract]   [Full Text] [Related]  

  • 35. [Sleepiness attacks while driving: adverse effects of new antiparkinson drugs].
    Miranda M; Díaz V; Venegas P; Villagra R
    Rev Med Chil; 2001 May; 129(5):585-6. PubMed ID: 11464545
    [No Abstract]   [Full Text] [Related]  

  • 36. The use of amphetamine induced stereotyped behaviour as a model for the experimental evaluation of antiparkinson agents.
    Costall B; Naylor RJ; Wright T
    Arzneimittelforschung; 1972 Jul; 22(7):1178-83. PubMed ID: 4404343
    [No Abstract]   [Full Text] [Related]  

  • 37. Heat dyscontrol syndrome in patients receiving antipsychotic, antidepressant and antiparkinson drug therapy.
    Reimer DR; Mohan J; Nagaswami S
    J Fla Med Assoc; 1974 Jul; 61(7):573-4. PubMed ID: 4152488
    [No Abstract]   [Full Text] [Related]  

  • 38. [Current status of antiparkinson therapy].
    Pendefunda G
    Rev Med Chir Soc Med Nat Iasi; 1977; 81(1):151-6. PubMed ID: 866829
    [No Abstract]   [Full Text] [Related]  

  • 39. [A new antiparkinson agent. Pergolide].
    Boas J
    Ugeskr Laeger; 1994 Oct; 156(44):6563-5. PubMed ID: 7825262
    [No Abstract]   [Full Text] [Related]  

  • 40. [Abnormal diurnal somnolence, "sleep attacks" and antiparkinson drugs].
    Rascol O; Ferreira J; Montastruc JL
    Rev Neurol (Paris); 2001 Oct; 157(10):1313-23. PubMed ID: 11885528
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.